Table 3 Prognostic value of NUCB2 protein expression for the BCR-free survival in univariate and multivariate analyses by Cox regression
From: Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer
Covariant | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
Exp (B) | 95% CI | P value | Exp (B) | 95% CI | P value | |
NUCB2 protein expression (high/low) | 2.306 | 1.501-3.544 | <0.001 | 2.535 | 1.643-3.911 | <0.001 |
Gleason score (> 7/7/< 7) | 1.703 | 1.280-2.265 | <0.001 | 1.846 | 1.384-2.460 | <0.001 |
PSA (>10/4-10/< 4) | 1.241 | 0.705-2.188 | 0.454 | |||
Age (≥65/< 65) | 1.068 | 0.804-1.419 | 0.650 | |||
Angiolymphatic invasion (presence/absence) | 1.084 | 0.814-1.443 | 0.580 | |||
Surgical margin status (presence/absence) | 1.017 | 0.709-1.459 | 0.925 | |||
PCa Stage (T2, T3/T1) | 1.090 | 0.921-1.291 | 0.316 | |||
Lymph node metastasis (presence/absence) | 1.140 | 0.850-1.528 | 0.381 | |||
Seminal vesicle invasion (presence/absence) | 1.505 | 1.132-2.003 | 0.005 | 1.538 | 1.154-2.048 | 0.003 |